About Altimmune
Altimmune is a company based in Gaithersburg (United States) founded in 1997 was acquired by PharmAthene in January 2017.. Altimmune has raised $58 million across 23 funding rounds from investors including NIH, HHS and U.S Army. The company has 59 employees as of December 31, 2024. Altimmune has completed 1 acquisition, including Immune Targeting Systems. Altimmune operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Biological E, Mirum Pharmaceuticals and Adocia, among others.
- Headquarter Gaithersburg, United States
- Employees 59 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Altimmune, Inc.
-
Annual Revenue
$20 K-95.31as on Dec 31, 2024
-
Net Profit
$-95.06 M-7.48as on Dec 31, 2024
-
EBITDA
$-102.93 M-23.97as on Dec 31, 2024
-
Total Equity Funding
$58 M (USD)
in 23 rounds
-
Latest Funding Round
$4.7 M (USD), Grant
Jun 29, 2020
-
Investors
NIH
& 11 more
-
Employee Count
59
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
PharmAthene
(Jan 19, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Altimmune
Altimmune is a publicly listed company on the NASDAQ with ticker symbol ALT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Altimmune
Altimmune has successfully raised a total of $58M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $4.7 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 23
- Last Round Grant — $4.7M
-
First Round
First Round
(01 Jun 2001)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Grant - Altimmune | Valuation |
investors |
|
| Aug, 2019 | Amount | Grant - Altimmune | Valuation |
investors |
|
| Sep, 2018 | Amount | Grant - Altimmune | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Altimmune
Altimmune has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and U.S Army. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Altimmune
Altimmune has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immune Targeting Systems. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell vaccines against mutating viruses are discovered and developed.
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Altimmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Altimmune Comparisons
Competitors of Altimmune
Altimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Biological E, Mirum Pharmaceuticals and Adocia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Altimmune
Frequently Asked Questions about Altimmune
When was Altimmune founded?
Altimmune was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Where is Altimmune located?
Altimmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of Altimmune?
Vipin K Garg is the current CEO of Altimmune.
Is Altimmune a funded company?
Altimmune is a funded company, having raised a total of $58M across 23 funding rounds to date. The company's 1st funding round was a Grant of $24.1M, raised on Jun 01, 2001.
How many employees does Altimmune have?
As of Dec 31, 2024, the latest employee count at Altimmune is 59.
What is the annual revenue of Altimmune?
Annual revenue of Altimmune is $20K as on Dec 31, 2024.
What does Altimmune do?
Altimmune was founded in 1997 and is based in Gaithersburg, United States, within the biotechnology sector. Focus is placed on developing vaccines and immunotherapies targeting infectious diseases like influenza and hepatitis B, alongside treatments for solid tumors and related conditions. Products under development include NasoVAX for intranasal influenza vaccination, HepTcell for chronic hepatitis B, ALT-801 for non-alcoholic steatohepatitis, T-COVID for intranasal COVID-19 therapy, and NasoShield for anthrax protection.
Who are the top competitors of Altimmune?
Altimmune's top competitors include Nimbus Therapeutics, Adocia and Biological E.
Is Altimmune publicly traded?
Yes, Altimmune is publicly traded on NASDAQ under the ticker symbol ALT.
How many acquisitions has Altimmune made?
Altimmune has made 1 acquisition, including Immune Targeting Systems.
Who are Altimmune's investors?
Altimmune has 12 investors. Key investors include NIH, HHS, U.S Army, PharmAthene, and Truffle Capital.
What is Altimmune's ticker symbol?
The ticker symbol of Altimmune is ALT on NASDAQ.